Dr. Schense’s extensive experience in the pharmaceutical and medical device fields in European and US regulatory strategy, development strategy, clinical study design, and program management, in addition to his strong background in regenerative medicine, makes him an excellent addition to our team.
ROCHELLE, Va. (PRWEB) July 11, 2018
NDA Partners Chairman Carl Peck, MD, announced today that Jason Schense, PhD, a senior biopharma industry executive and former Chief Technology Officer of Kuros Biosciences AG, has joined the firm as an Expert Consultant. Dr. Schense has extensive experience in the pharmaceutical and medical device fields in European and US regulatory strategy, development strategy, clinical study design, preclinical development, and program management. Dr. Schense has a strong technical background in regenerative medicine and has worked on a variety of products for dental and oral health, orthopedics, trauma, and wound healing applications including medical devices, drugs, and combination products.
Prior to joining NDA Partners, Dr. Schense served as Chief Technology Officer, Kuros Biosciences AG, where he was responsible for the company’s R&D. He is a founder of Kuros Biosurgery AG (now Kuros Biosciences AG) and successfully lead the startup into product development, then transitioned into project management and executive management serving as the Executive Director, Spine & Trauma.
“Dr. Schense’s extensive experience in the pharmaceutical and medical device fields in European and US regulatory strategy, development strategy, clinical study design, and program management, in addition to his strong technical background in regenerative medicine working on medical devices, drugs, and combination products, makes him an excellent addition to our team of Expert Consultants,” said Dr. Peck. “We are very pleased to welcome him to NDA Partners.”
Dr. Schense earned his doctorate and Master of Science degree from the California Institute of Technology’s Department of Chemical Engineering and a Bachelor of Science degree in Chemical Engineering from Massachusetts Institute of Technology. He conducted his postdoctoral research at ETH – Zurich’s Department of Materials in Biomedical Engineering.
About NDA Partners
NDA Partners is a life sciences management consulting firm focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and management of client product development programs.
Earle Martin, Chief Executive Officer